The Taiwan biotech industry maintained significant profitability in 2025, with at least 10 companies earning more than one share capital and over 20 firms reporting an EPS exceeding NT$5. While foreign exchange fluctuations and a cooling global economy slightly tempered growth compared to 2024, the sector’s operational core remains resilient.

• Vision Care Dominance: The "Eye-Sector" demonstrated the most consistent performance. Pegavision led the pack with an EPS of $20.87, followed by Visco, which expanded its monthly capacity to 49 million pieces to meet surging demand for silicone hydrogel lenses in China and Japan. Other top performers included Universal Vision Biotechnology and Formosa Optical Technology.
• Group Synergy: Standard Chemical & Pharmaceutical Group emerged as the winning conglomerate. Its subsidiaries, Syngen Biotech and Syn-Tech Chem. & Pharm., reported EPS of $10.02 and $5.87, respectively. The parent company, Standard Chem & Pharm, hit a record EPS of $5.19 and resumed stock dividends for the first time in 15 years to fund further plant expansions.
• Watch List: Market eyes remain on Bora Pharmaceuticals and Lotus , whose upcoming financial disclosures are expected to potentially reshuffle the leaderboard.

Resource: 生技2025獲利旺 眼球股吸睛